Adaptimmune Therapeutics Plc Cash Flow Quality Index

Latest as of June 2024: 0.68x

Adaptimmune Therapeutics Plc cash flow quality index. Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow Quality Index of 0.68x as of June 2024. Operating cash flow of $47.39 Million is below net income of $69.52 Million, suggesting accrual-heavy earnings not yet converted to cash. See ADAP financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

0.68x

Operating CF / Net Income

Operating Cash Flow

$47.39 Million

USD

Net Income

$69.52 Million

USD

Data as of

Jun 2024

Most recent filing

Adaptimmune Therapeutics Plc Cash Flow Quality Index by Year (None–None)

Adaptimmune Therapeutics Plc cash flow quality index by year from None to None. Year-by-year earnings quality comparison for Adaptimmune Therapeutics Plc. For the full cash flow conversion analysis, see ADAP operating cash flow.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.